Background: Besides improving glucose control, sodium glucose cotransporter 2 inhibition with dapagliflozin reduces blood pressure, body weight and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes (T2DM). The Parameter Response Efficacy (PRE) score was developed to predict how short-term drug effects on cardiovascular risk markers translate into long-term changes in clinical outcomes. We applied the PRE score to clinical trials of dapagliflozin to model the effect of the drug on kidney and heart failure (HF) outcomes in patients with T2DM and impaired kidney function.
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Introduction
Approximately 40% of patients with diabetes develop chronic kidney disease.
[1] Both diabetes and chronic kidney disease are powerful risk factors for end stage kidney disease and cardiovascular disease. In addition, emerging data demonstrate a strong association between diabetes and heart failure. Patients with both diabetes and impaired kidney function are at particular high risk to develop heart failure. [2, 3] As a result, life expectancy among patients with diabetes and kidney disease and/or heart failure is shortened. [4] New therapies to decrease the risks of developing chronic kidney disease and heart failure are being developed.
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a relatively new class of oral anti-diabetic drugs, registered for use in patients with type 2 diabetes. Recent cardiovascular outcome trials have demonstrated that the SGLT2 inhibitors empagliflozin, canagliflozin and dapagliflozin reduce the risk of heart failure and slow kidney disease progression in patients with type 2 diabetes at cardiovascular risk or with established cardiovascular disease. [5] [6] [7] The marked efficacy of these drugs to delay disease progression are unlikely to be explained by their effects on HbA1c alone. Indeed, a study comparing glimepiride against canagliflozin concluded that the beneficial effects of canagliflozin in slowing estimated glomerular filtration rate (eGFR) decline were independent of its glycemic effects.
[8] Furthermore, in hypertensive patients with type 2 diabetes (T2DM) who were using ACE-inhibitors or Angiotensin Receptor Blockers, HbA1c lowering by dapagliflozin only modestly explained the overall 35% reduction in urine albumin to creatinine ratio (UACR).
[9] The multiple effects of SGLT2 inhibition including reductions in body weight, blood pressure, albuminuria and uric acid, in addition to reducing HbA1c, may contribute to the reduction in heart failure and kidney events observed in prior studies. [9] [10] [11] Because SGLT2 inhibition has effects on multiple cardiovascular risk markers, integrating changes in these multiple effects as opposed to using HbA1c alone to predict the long-term effect of SGLT2 inhibitors on kidney and heart failure outcomes seems sensible. The multiple Parameter Response Efficacy (PRE) score is an algorithm that has been developed to translate the effect of an intervention on multiple risk markers into a predicted long-term risk change on clinical outcomes.
[10] The PRE score was developed in clinical trials of renin-angiotensinaldosterone-system intervention and subsequently validated in clinical trials of renin-angiotensin-aldosterone-system intervention, PPAR-γ agonists, and endothelin receptor antagonists. [12] [13] [14] Randomized controlled trials investigating the long-term effects of SGLT−2 inhibition in patients with chronic kidney disease (CKD) are currently ongoing. The aim of this study was to apply the PRE score to phase 3 clinical trials with the SGLT2 inhibitor dapagliflozin in order to predict the potential benefit of dapagliflozin on kidney and heart failure outcomes in patients with T2DM and CKD.
Materials and methods

Data sources and patient population
Individual patient data were selected from a pooled database of phase 3 dapagliflozin clinical trials (n = 7) with an eGFR between 25 and 60 ml/min/m 2 and a UACR > 30 mg/g (Supplement Table 1 ). The study designs of these trials have been previously published. [15-21] Patients were then stratified into two groups, those with UACR > 30 mg/g (N = 350) and those with UACR > 200 mg/g (N = 132), in order to test the PRE score at varying levels of albuminuria. Patients with impaired eGFR and elevated albuminuria were selected as this population is also enrolled in the ongoing kidney outcome trials. Individual patient data from the placebo arm of the ALTITUDE trial were used for the background population to model the risk relations for different cardiovascular risk markers with kidney and heart failure outcomes. The design of the ALTITUDE trial has been previously published.
[22] This population included patients with type 2 diabetes and chronic kidney disease (defined as eGFR between 25 and 60 ml/min/1. 
Endpoint definition
The kidney outcome was defined as a composite of end stage kidney disease (ESKD) and a confirmed doubling of serum creatinine. The heart Prediction of the effect of dapagliflozin on renal and heart failure outcomes based on short-term changes in multiple risk markers failure outcome was defined as hospitalization due to congestive heart failure (CHF).
Risk marker selection
Parameters measured in the intention-to-treat population of the dapagliflozin phase 3 trials that were previously identified as risk markers for kidney or heart failure outcomes were used for analysis: Glycated hemoglobin (HbA1c), systolic blood pressure (SBP), UACR, body weight, hemoglobin (Hb), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), serum albumin, calcium, potassium phosphate and uric acid. UACR was measured in an untimed sample.
Statistical analysis
A Cox proportional hazards model was used to estimate the coefficients and hazard ratios associated with each risk marker for the first recorded kidney or heart failure event. The regression coefficients for each risk marker were taken and used as weights for the risk equation for kidney and heart failure outcomes. First, risk marker-outcome relationships were calculated in ALTITUDE over a median follow up of 2.8 years.
These calculated risk marker-outcome relationships were then applied to the baseline and week 24 (month 6) biomarker measurements of patients selected from the dapagliflozin trials to estimate risk of kidney and HF outcomes at both time points. The mean difference in the predicted risk in the dapagliflozin arm, adjusted for the mean difference in the predicted risk in the placebo arm, represents the PRE score and reflects an estimation of the expected kidney and heart failure risk reduction conferred by dapagliflozin treatment. Risk marker-outcome relationships were calculated in patients from the background population with UACR > 200 mg/g and UACR > 30 mg/g. These relationships were applied to patients included in the dapagliflozin phase 3 trials with UACR > 200 mg/g and UACR > 30 mg/g, respectively. The PRE score was calculated for subjects in the dapagliflozin phase 3 trials in whom all risk markers were measured at baseline and follow-up. To evaluate the influence of missing data, we applied multiple imputations to the data from the dapagliflozin phase 3 program by using a multilevel linear model (from R package 'mice'). Since the short-term change in albuminuria is a strong predictor of kidney outcomes we performed a simulation analysis to estimate the change in the risk of kidney outcomes at various levels of albuminuria reduction.
Means and standard deviation (SD) are provided for variables with a normal distribution, whereas median and 1st and 3rd quartile are provided for variables with a skewed distribution. Categorical variables are reported as frequencies and percentages. For continuous variables that are not normally distributed, such as UACR, a natural log transformation was applied before analysis. Two-sided p-values < 0.05 indicated statistical significance. All statistical analyses were conducted with R version 3.0.1 (R Project for Statistical Computing, www.r-project.org).
Results
In the background dataset 172 (8.0%) patients experienced a kidney event and 120 (5.5%) patients were hospitalized for congestive heart failure during a median follow-up of 2.8 years.
A total of 132 patients had UACR > 200 mg/g and 350 patients had UACR > 30 mg/g and were included in the analysis. Baseline characteristics of the populations from the ALTITUDE and dapagliflozin trials with UACR > 200 mg/g and > 30 mg/g are described in Table 1 and Supplement Table 2 , respectively.
Short-term risk marker changes
Changes in risk markers in patients with UACR > 200 mg/g after treatment with placebo and dapagliflozin 5 and 10 mg are shown in Figure 1 . In line with prior studies in patients with impaired kidney function, dapagliflozin modestly reduced HbA1c. Reductions in body weight, blood pressure, uric acid, UACR and increases in hemoglobin, albumin and phosphate were also observed. The direction and magnitude of the short-term risk marker changes were similar in patients with UACR > 30 mg/g (Supplement Figure 1 ).
Predicted treatment effect
In patients with UACR > 200 mg/g, the predicted risk change for the kidney endpoint with dapagliflozin based on the observed placebo corrected change in HbA1c alone was −0.9% (−1.6 to 0.0) and −2.5% (95%CI −4.5 to -0.1) with dapagliflozin 5 mg and dapagliflozin 10 mg, respectively ( Figure 2 ). Based on albuminuria lowering effects alone, the predicted risk change in kidney endpoints was −34.1% (−39.5 to −27.3) and −27.7% (95%CI −32.7 to −22.0), respectively. Integrating all short-term biomarker changes resulted in a predicted risk change of −40.6% (−52.3 to −28.9) and −40.8% (95%CI −51.7 to −29.4) with dapagliflozin 5 mg and dapagliflozin 10 mg. The predicted risk change for hospitalization due to heart failure based on the PRE score was −23.8% (−43.4 to −4.7) and −27.3% (−47.7 to −5.1), respectively.
In patients with UACR > 30 mg/g, the predicted risk change for the kidney endpoint was −47.6% (−55.9 to −37.1) and −40.4% (95%CI 
Phosphate (mg/dl) 3.8 (0.7) 3.6 (0.5) 3.7 (0.6) 3.8 (0.4) 0.47
Uric acid (mg/dl) 7.2 (1.7) 6.7 (1.7) 7.3 (1.7) 7.5 (1.9) 0.08
Calcium (mg/dl) 9.3 (0.5) 9.6 (0.4) 9.4 (0.5) 9.6 (0.5) 0.17
Numeric variables are presented as mean (SD) if normally distributed. UACR is presented as median [IQR] . Categorical variables are presented as frequency (%). BP, blood pressure; UACR, urine protein: urine creatinine ratio; HDL, high density lipoprotein; LDL, low density lipoprotein. *P-value for the difference between placebo and dapagliflozin. *P < 0.05,**P < 0.01,***P < 0.001 compared to placebo. HbA1c, glycated hemoglobin; SBP, systolic blood pressure; UACR, urine albumin to creatinine ratio; LDL-C, low density lipoprotein; HDL-C, high density lipoprotein; Hb, hemoglobin; K, potassium. Prediction of the effect of dapagliflozin on renal and heart failure outcomes based on short-term changes in multiple risk markers 
Simulations and sensitivity analyses
Since albuminuria change is a strong predictor for kidney outcomes, additional simulations were performed in order to predict the risk changes for varying levels of albuminuria changes induced by dapagliflozin ( Figure 3 ). These simulation analyses revealed that a 10% decrease in UACR, instead of the observed decrease of 35%, would have resulted in an estimated kidney risk reduction of 26.8% and 26.5% in patients with UACR > 200mg/g and UACR > 30 mg/g, respectively. 
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In a sensitivity analysis we assessed the impact of missing values. In the dapagliflozin trials, data were missing in 9.5% of patients at baseline and in 25.1% of patients at month 6. There were very few missing baseline data across the ALTITUDE background dataset (< 0.01%). There were no differences in baseline characteristics between the patients with complete biomarker data and the total selected population from the dapagliflozin trials (n = 350). Short-term changes in risk markers in the analysis population remained similar after multiple imputations. In patients with UACR > 200 mg/g, the predicted kidney risk changes with dapagliflozin 5 and 10 mg after multiple imputation were −44.1% (−55.1 to −32.6) and −38.5% (−47.2 to −28.7), respectively. The predicted risk changes for hospitalizations due to heart failure were −24.0% (−46.0 to −3.1) and −24.7% (−43.6 to −5.0), respectively (Supplement Figure 2) . After multiple imputations, predicted risk changes for kidney and heart failure outcomes for patients with UACR > 30 mg/g did not differ from those in the main analysis without multiple imputations (Supplement Figure 3) .
Discussion
Changes in biomarkers can be used to monitor and predict the efficacy of therapies to decrease the risk of kidney and cardiovascular outcomes. In this study we used an algorithm that translates the short-term effect of an intervention on multiple risk markers into a predicted long-term risk change on clinical outcomes. The algorithm was used to predict the effect of dapagliflozin on kidney and heart failure outcomes in patients with type 2 diabetes and CKD. Our results indicate that treatment with dapagliflozin would confer considerable improvements in kidney and heart failure outcomes in these patients. These results support a large dapagliflozin outcome trial to confirm long-term safety and efficacy in reducing adverse clinical events.
As with most short-term clinical trials testing the effects of SGLT-2 inhibitors, the dapagliflozin trials included in this study were primarily designed to assess effects of dapagliflozin on HbA1c.[15-17, 19-21, 23] Our analysis suggests that glycemic effects of dapagliflozin only modestly contribute in reducing risk of kidney outcomes. Non-glycemic effects of dapagliflozin, in particular the albuminuria lowering properties, are probably more important contributors of the predicted effects on kidney outcomes. Indeed, prior studies have suggested that albuminuria lowering is key to reduce kidney outcomes. [24, 25] A meta-analysis of cardiovascular events across the dapagliflozin phases 2b and 3 program suggested beneficial effects of dapagliflozin on cardiovascular and heart failure outcomes.
[26] In line with these results, empagliflozin reduced the occurrence of hospitalization for HF with 35% in the EMPA-REG OUTCOME trial and by 39% in the subgroup of patients with diabetes and kidney disease.
[27] Likewise, another large-scale cardiovascular outcome study, the Canagliflozin Cardiovascular Assessment Study (CANVAS), reported a decrease in hospitalization for HF of 33% in patients randomised to canagliflozin versus placebo.
[7] The recently completed Dapagliflozin Effect on Cardiovascular Events -Thrombolysis in Myocardial Infarction 58 (DECLARE -TIMI 58) trial investigated the effects of dapagliflozin in patients at high cardiovascular risk and reported that dapagliflozin reduced the occurrence of the composite kidney outcome with 47%. Furthermore, risk for hospitalization due to heart failure decreased by 27% on dapagliflozin.
[5] These observed effects are very similar to our PRE score predictions in patients with elevated albuminuria. The ongoing DAPA-CKD trial, described in the companion article, will provide a more clear answer whether the predicted effects of dapagliflozin in patients with CKD are accurate. [28] Although the mechanisms underlying the multipotent action of SGLT2-inhibitors are not completely understood, several lines of evidence suggest that the normalization of tubuloglomerular feedback plays a key role in the renoprotective effects.
[29] Additionally, dapagliflozin-induced natriuretic/osmotic diuresis and the resultant volume contraction may contribute to enhanced fluid clearance from the interstitial space and explain the reduction in heart failure risk.[30-32] However, the favorable cardiorenal effects of dapagliflozin are potentially counterbalanced by other non-beneficial effects, including alterations in calcium and phosphate homeostasis.
[33] Prior studies have shown modest increases in phosphate during dapagliflozin therapy that were explained by increased activity of the Na Prediction of the effect of dapagliflozin on renal and heart failure outcomes based on short-term changes in multiple risk markers in serum phosphate levels observed in our analysis translated into a small increase in estimated kidney and heart failure risk. Yet, the benefits associated with improvements in multiple risk markers outweighed this small increase in risk.
What is the applicability of the PRE score for future clinical trials and patient care? Changes in single risk markers often insufficiently predict the long-term drug effect on clinical outcomes, as shown by multiple clinical trials. [22, [36] [37] [38] Integrating multiple short-term risk marker changes has the potential to better predict long-term treatment effects.
[39] Accurate long-term risk prediction is important to better predict the long-term effect of a drug in daily patient care as well as to improve the design of clinical trials. As such, the PRE score can be used in clinical practice to better predict the long-term effect of a drug for an individual patient and during early drug development to determine if a new drug is likely to be effective and to inform power and sample size calculations. [39] A main limitation of this study is that we could not include all relevant biomarkers that are associated with kidney and heart failure outcomes. For example, we ideally would have used NT-proBNP as a marker for volume status instead of body weight, since the latter may merely represent initial volume contraction rather than sustained alterations in fluid handling. In addition, the number of patients with UACR > 200 mg/g and eGFR 30 -60 was relatively small which limits the precision of our effect estimates. Furthermore, some patients did not use concomitant RAAS inhibition. In the ongoing kidney outcome trials of SGLT2 inhibitors, nearly all patients are receiving RAAS inhibition. We don't believe however this influences our predictions as it has been shown that the effects of dapagliflozin on all cardiovascular risk markers included in our analysis are consistent regardless of concomitant RAAS inhibition. [40] In conclusion, the PRE score predicted clinically meaningful reductions in kidney and heart failure endpoints associated with dapagliflozin therapy in patients with diabetic kidney disease. These results support a large long-term outcome trial in this population to confirm the benefits of the drug on these endpoints. Diabetes 
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Supplementary files
Supplementary Supplementary Table 3 . Predicted risk change for kidney and heart failure outcomes for patients with UACR > 30 mg/g, after multiple imputation (n = 350). Results are given as mean (95%CI). Following page: Supplementary Figure 1 . Predicted risk change for kidney (A) and heart failure (B) outcomes for patients with UACR > 30 mg/g, based on changes in single risk markers and the integrated effects of all risk markers. Results are given for dapagliflozin 5 mg and dapagliflozin 10 mg. Bars indicate percentage mean change in relative risk induced by treatment corrected for placebo and is given with 95% confidence intervals. * Change in UACR is given as percentage change.
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